 Plasma concentrations at each time point, Tmax, Fluctuation, and any ln-transformed pharmacokinetic parameter where the observed intra-subject CV of the reference product is less than 30 swr 0.294, will be evaluated using the average unscaled bioequivalence ABE approach will be used. The MIXED procedure of SAS will be used in this case with a statistical model that includes terms for Sequence, Site, SequenceSite, Subject nested within SequenceSite, Period nested within Site, Treatment, and if necessary, TreatmentSite. A separate statistical analysis will be done to determine if the TreatmentSite term is statistically significant p0.05 and needs to be retained in the model. If this term is not significant, it will be dropped from the statistical model for the definitive statistical evaluation. The ratio of geometric means TR and 90 confidence intervals for the ratio, based on least-squares means from the analysis of the log-transformed PK Parameter, will be calculated. 